Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (111-120 of 171) with videos related to

Pageof 18
Sort By:
European Journal of Heart Failure|January 3, 2006
Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFTMaylene Wong, Lidia Staszewsky, Elisa Carretta, et al.
American Journal of Hypertension|August 4, 2004
Determinants of radial artery pulse wave analysis in asymptomatic individualsDaniel A Duprez, Daniel R Kaiser, Wayne Whitwam, et al.
Journal of Cardiac Failure|February 18, 2004
Definition, classification, and staging of the adult cardiomyopathies: a proposal for revisionThomas D Giles, Kanu Chatterjee, Jay N Cohn, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 16, 2004
Antihypertensive utility of perindopril in a large, general practice-based clinical trialStevo Julius, Jay N Cohn, Joel Neutel, et al.
American Heart Journal|October 18, 2003
Screening for early detection of cardiovascular disease in asymptomatic individualsJay N Cohn, Lynn Hoke, Wayne Whitwam, et al.
European Journal of Heart Failure|November 11, 2003
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Jay N Cohn, Marc A Pfeffer, Jean Rouleau, et al.
Journal of the American College of Cardiology|June 3, 2004
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic dataMaylene Wong, Lidia Staszewsky, Roberto Latini, et al.
Lancet (London, England)|April 4, 2003
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational studyStefan D Anker, Abdissa Negassa, Andrew J S Coats, et al.
European Journal of Heart Failure|November 24, 2004
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFTHenry Krum, Peter Carson, Csaba Farsang, et al.
Circulation|February 18, 2004
Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathyBarry J Maron, Venkatakrishna N Tholakanahalli, Andrey G Zenovich, et al.
Pageof 18

Showing results (111-120 of 171) with videos related to

Sort By:
Pageof 18
European Journal of Heart Failure|January 3, 2006
Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFTMaylene Wong, Lidia Staszewsky, Elisa Carretta, et al.
American Journal of Hypertension|August 4, 2004
Determinants of radial artery pulse wave analysis in asymptomatic individualsDaniel A Duprez, Daniel R Kaiser, Wayne Whitwam, et al.
Journal of Cardiac Failure|February 18, 2004
Definition, classification, and staging of the adult cardiomyopathies: a proposal for revisionThomas D Giles, Kanu Chatterjee, Jay N Cohn, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 16, 2004
Antihypertensive utility of perindopril in a large, general practice-based clinical trialStevo Julius, Jay N Cohn, Joel Neutel, et al.
American Heart Journal|October 18, 2003
Screening for early detection of cardiovascular disease in asymptomatic individualsJay N Cohn, Lynn Hoke, Wayne Whitwam, et al.
European Journal of Heart Failure|November 11, 2003
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Jay N Cohn, Marc A Pfeffer, Jean Rouleau, et al.
Journal of the American College of Cardiology|June 3, 2004
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic dataMaylene Wong, Lidia Staszewsky, Roberto Latini, et al.
Lancet (London, England)|April 4, 2003
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational studyStefan D Anker, Abdissa Negassa, Andrew J S Coats, et al.
European Journal of Heart Failure|November 24, 2004
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFTHenry Krum, Peter Carson, Csaba Farsang, et al.
Circulation|February 18, 2004
Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathyBarry J Maron, Venkatakrishna N Tholakanahalli, Andrey G Zenovich, et al.
Pageof 18